News Hub | News Direct

All Industries


Article thumbnail News Release

Fah Mai Holdings' Jacob Carter provides expert insights on whisky investment

Fah Mai Holdings Group Inc

Fah Mai Holdings Group Inc (OTC:FMHG) UK head and manager of @whiskybullauctions Jacob Carter provides detailed advice for investors in the secondary whisky bottle market in an interview with Proactive's Stephen Gunnion. Carter emphasised the importance of conducting thorough research and developing a personal investment strategy, highlighting rarity and age as key factors in choosing investment bottles. He mentioned significant past investment successes, such as a 1964 Black Bowmore Aston Martin DB5 bottle bought for less than £100 and now valued at about £50,000. Carter advised using resources like Rare Whisky 101 to access data on highly traded bottles and stressed the necessity of understanding market dynamics, which can be influenced by distillery release schedules and other seasonal factors. He also discussed the critical aspects of storage and insurance for investment bottles, suggesting that collectors work with auction houses that provide these services. Authenticity verification, according to Carter, can involve checking cask and bottle numbers or consulting with distilleries directly. Contact Details Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

May 09, 2024 07:08 AM Eastern Daylight Time

Video
Article thumbnail News Release

Seeing Machines advances with strategic expansions and strong quarterly performance

Seeing Machines Ltd

Seeing Machines Ltd CEO Paul McGlone joins Proactive's Stephen Gunnion with an update on the company's progress and key developments. McGlone highlighted the expansion with an existing US customer and a tier 1 supplier, driven by increasing regulatory requirements in Europe, which signifies a significant development for the company. This expansion includes new technology integrations and a stronger foothold in the European market, alongside additional volume in China. Further, McGlone discussed the company's recent performance following their third-quarter results, noting a return to normal production levels and the launch of a new major vehicle program. This contributed to Seeing Machines producing over 300,000 vehicles in the quarter, supporting a year-on-year growth rate of 100%. This performance reassured investors of the company's growth trajectory. Additionally, McGlone outlined the launch of their biggest ever production award with a significant European OEM, which includes a comprehensive interior sensing capability for driver and occupant monitoring. This project is seen as a major technical achievement and is expected to notably increase growth rates. McGlone also touched on the aftermarket segment, particularly their Guardian Connections system for trucks and buses, which showed consistent growth and is set to expand further with the rollout of their third-generation product. Lastly, McGlone reaffirmed the company's financial targets for 2024 and their aim to achieve cash break-even in 2025, indicating strong momentum across various business areas, including automotive, aviation, and fleet services. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 09, 2024 07:06 AM Eastern Daylight Time

Video
Article thumbnail News Release

Light Science Technologies CEO discusses record 2023 results and strategic growth

Light Science Technologies Holdings PLC

Light Science Technologies Holdings PLC (AIM:LST) reported a record year in 2023 with CEO Simon Deacon highlighting significant achievements in an interview with Proactive's Stephen Gunnion. The company implemented a strategic plan focused on growth and profitability, exceeding expectations in both areas. Notably, its Controlled Environment Agriculture (CEA) segment and Contract Electronics Manufacturing (CEM) contributed robustly to revenue increases. The company achieved a gross margin of 23.4% and overall revenue growth of 13.8% to £9.3 million. Deacon also discussed the impact of strategic acquisitions, including Tomtech, which enhanced its offerings in controlled environment agriculture, integrating systems for vertical farms, polytunnels, and glasshouses. Another notable acquisition was Injecta Fire Barrier, a key asset in the passive fire protection market, poised for growth due to regulatory changes spurred by the Fire Safety Act of 2021. Additionally, the CEO outlined the use of a £1.45 million fundraise to support product development, acquisitions, and extend its cash runway. Looking forward, Deacon detailed milestones for 2024, including a significant contract in the sports entertainment electronics segment and anticipated revenue growth in passive fire protection. Overall, Deacon remains optimistic about sustaining momentum and achieving further growth. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 09, 2024 07:03 AM Eastern Daylight Time

Video
Article thumbnail News Release

Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones

Immunic Inc

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Vitt said the quarter was notable for Immunic's successful fundraising efforts, raising up to $240 million in a three-tranche private placement aimed at furthering its Multiple Sclerosis (MS) and gastrointestinal treatments. He also highlighted the importance of the recent allowance of a fourth US patent for vidofludimus calcium, enhancing its intellectual property portfolio around MS treatments and ensuring long-term commercial exclusivity. Vitt gave an update on the status of ongoing clinical trials, including the advanced Phase 2 CALLIPER trial for MS, with significant results expected in April next year. Moreover, he touched on Immunic's gastrointestinal disorder programs, particularly for celiac disease, with the IMU-856 program showing promising results in restoring gut wall functions. The interview also covered upcoming milestones, focusing on executing current clinical trials and preparing for future phases. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 09, 2024 06:58 AM Eastern Daylight Time

Video
Article thumbnail News Release

Sostravel.com strategy unveiled: interview with Edoardo Zarghetta

SosTravel.com

SosTravel.com (OTCQB:SOSAF, EURONEXT:SOS) investor relations head Edoardo Zarghetta outlines the company's operations and strategic directions in an interview with Proactive's Stephen Gunnion. Sostravel.com operates primarily as a digital travel technology company with two business units. One focuses on packaging holidays, primarily in destinations such as Sardinia, southern Italy, Kenya, Turkey, Egypt, and Cuba, managing hotels and resorts to create custom holiday packages. The second unit provides technology services, including a Lost Luggage Concierge and Dr Travel for telehealth needs, enhancing travellers' experiences by addressing common issues like lost luggage and health care in foreign locales. The company benefits from a commercial relationship with shareholder TraWell Co SpA (OTCQX:TRWAF), which markets Sostravel.com's services at airports, enhancing visibility and customer acquisition. This relationship allows the implementation of unique marketing strategies focused on leveraging travel needs to introduce value-added services, distinguishing Sostravel.com from competitors by creating a symbiotic ecosystem between holiday offers and service provision. The company reported a 29.6% increase in gross booking value as of March and projects significant growth in revenues and EBITDA for 2024, with updates expected in August to confirm these forecasts. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 09, 2024 06:56 AM Eastern Daylight Time

Video
Article thumbnail News Release

Hostelworld CEO discusses strategic growth and market share increase

Hostelworld Group PLC

Hostelworld Group PLC (LSE:HSW, OTC:HSWLF) CEO Gary Morrison highlights significant advancements in the company's strategy and operational results in an interview with Proactive's Stephen Gunnion. The company, a key player in online hostel bookings, introduced social features in its app about two and a half years ago, aiming to enhance user interaction by connecting travellers based on their destination and stay dates. These features have been pivotal in increasing app downloads and subsequently, app-based bookings, which have grown 49% year-over-year, compared to a 27% increase in web bookings. Hostelworld's innovative social strategy, designed to cater primarily to solo travellers aged 18 to 35, has significantly boosted its market share. This strategy, coupled with an effective marketing approach, has led to a 34% increase in revenue and a 37% increase in net bookings year-over-year. Morrison also noted a geographical shift in the company's market, with substantial growth in Asia and continued strong performance expected in various global markets. Furthermore, he discussed the company's financial health, mentioning efficient cash conversion from EBITDA and strategic financial decisions, including a share repurchase program to offset dilution from previous share issuances. Looking forward, Hostelworld anticipates continued revenue and bookings growth, aligning with its strategic projections established in November 2021. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

May 09, 2024 06:52 AM Eastern Daylight Time

Video
Article thumbnail News Release

One Health Group sets another record for new patients choosing One Health through Patient Choice

One Health Group PLC

One Health Group PLC (AQSE:OHGR) CEO Adam Binns joined Proactive's Stephen Gunnion with details of a full-year trading update that showed revenue of more than £23 million for the year to 31 March 2024, and net year-end cash of £4.7 million, which will fund investment in future growth and underpin its progressive dividend policy. Binns explained that One Health Group operates as an independent provider of NHS services in the UK, specifically targeting various local economies with subcontracted health services. The company, established 22 years ago, focuses on providing non-surgical treatments and surgical interventions through subcontracted consultants and facilities. He emphasised patient choice, enabling patients to select their healthcare provider through GP referrals or directly from NHS waiting lists. One Health Group also boasts a rapid treatment timeline of 6 to 8 weeks compared to traditional NHS routes. Strategically, One Health Group is expanding its geographical footprint across the UK, moving into regions like Manchester and Coventry, with plans to increase their owned capacity for more efficient service delivery. Additionally, it secured two new five-year contracts with the NHS, reflecting confidence in its service quality and operational stability. Overall, One Health Group's model of integrating NHS and subcontracted services aims to alleviate pressure on NHS resources while maintaining high standards of patient care and operational efficiency. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

May 09, 2024 06:48 AM Eastern Daylight Time

Video
Article thumbnail News Release

Fusion Antibodies reports second-half rebound as new commercial strategy pays off

Fusion Antibodies PLC

Fusion Antibodies PLC (AIM:FAB) CEO Adrian Kinkaid joined Proactive's Stephen Gunnion with more on the company that specialises in various stages of antibody development, excluding GMP production for clinical trials. He described Fusion Antibodies as a collaborative research organisation that engages deeply with clients to develop therapeutic antibodies, one of the most complex scientific endeavours. Its client base includes small VC-funded biotechs and has expanded to include large organisations like the National Cancer Institute. Fusion Antibodies also explores adjacent markets such as diagnostics, family medicine, and veterinary medicine. Recently, the company faced economic challenges, particularly a decrease in venture capital for biotechs, impacting its core business. However, it responded with strategic diversifications and cost management, leading to a 47% increase in fourth-quarter 2024 sales compared to the first quarter. The order pipeline at the year's end was significantly stronger at £750,000, promising a solid foundation for future growth. Kinkaid noted that Fusion Antibodies has secured various agreements, including a notable collaboration with the National Cancer Institute to employ their OptiMAL technology platform for discovering human antibodies. This platform could potentially lead to multiple licensing opportunities due to its vast diversity. Additionally, the company raised about £1.37 million, which will fund growth initiatives, including expanding its commercial team to better reach its primary market in the USA. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

May 09, 2024 06:41 AM Eastern Daylight Time

Video
Article thumbnail News Release

Royal Helium Secures $6 Million in Bought Deal Offering to Fuel Expansion and Well Development

Royal Helium Ltd

Royal Helium CEO Andrew Davidson joined Steve Darling from Proactive to announce the successful completion of a bought deal public offering that raised $6 million. The offering was conducted in conjunction with underwriting firms Canaccord Genuity, Cormark Securities, and Eight Capital Corp. Davidson detailed that the proceeds are designated for a robust exploration and development agenda. This includes drilling potential new wells at the company’s 40-mile site in Alberta and enhancing the development of existing wells in Saskatchewan. The capital will also bolster operational scaling and improve working capital to facilitate the company's ongoing progress toward self-funding from operational outputs. He highlighted the strategic importance of this capital injection, noting it supports Royal Helium's expansion from managing a single asset to multiple assets. Davidson emphasized the critical nature of this funding in ensuring the company does not miss another exploration season, thereby maintaining momentum in its growth and development strategy. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

May 08, 2024 05:28 PM Eastern Daylight Time

Video
1 ... 209210211212213 ... 3754